Chikungunya Vaccine, Recombinant (Cvx 329) Dosage
Medically reviewed by Drugs.com. Last updated on Apr 1, 2025.
Applies to the following strengths: preservative-free
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Chikungunya Fever
0.8 mL IM as a single dose
Use: For the prevention of disease caused by chikungunya virus
Usual Pediatric Dose for Chikungunya Fever
12 years and older: 0.8 mL IM as a single dose
Use: For the prevention of disease caused by chikungunya virus
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
CONTRAINDICATIONS:
- History of severe allergic reaction (e.g., anaphylaxis) to the active component or any of the ingredients
Safety and efficacy have not been established in patients younger than 12 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- For IM use
- Visually inspect product for particulate matter and discoloration prior to administration; discard if present.
- Immediately before administration, shake the prefilled syringe vigorously to form a homogeneous, cloudy white suspension.
- Due to the risk of syncope with injectable vaccines, ensure that procedures are in place to prevent injury before vaccination.
Storage requirements:
- Store refrigerated at 2C to 8C (36F to 46F) in the original carton to protect from light; do not freeze.
- After removal from refrigeration, this product may remain at room temperature up to 25C (77F) for up to 2 hours; discard if not used within the recommended time.
General:
- Report adverse events to the manufacturer by calling 1-833-365-9596 or emailing drug.safety@bavarian-nordic.com, or through the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or online at www.vaers.hhs.gov.
Patient advice:
- Understand that this vaccine may not protect all recipients; personal precautions should be taken reduce exposure to mosquito bites.
- Report any adverse effects to your health care provider, the vaccine manufacturer, or the VAERS.
- Women of childbearing potential: Consider enrolling in the pregnancy registry if exposed to this drug around the time of conception or during pregnancy.
More about chikungunya vaccine, recombinant (cvx 329)
Patient resources
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.